IGT PHARMA STARTS HUMAN TRIAL WITH ANHYDROVINBLASTINE (AVLB) FOR THE TREATMENT OF LUNG CANCER
Management is pleased to announce that the first patient has been treated with IGT's new drug, Anhydrovinblastine. The clinical trial is a Phase I study for the use of Anhydrovinblastine in the treatment of advanced solid tumors including non-small cell lung cancer. This is a single center, open label, non-randomized Phase 1 study. This study will be conducted at the Roswell Park Cancer Institute in Buffalo, New York and will assess the safety and tolerability of Anhydrovinblastine in these patients.
The study will enroll up to 30 patients with advanced solid cancers. The clinical trial will determine the maximum tolerated dose (MTD) and the dose limiting toxicities (DLT) of AVLB on an escalating dose basis. The clinical investigators will assess the safety profile of AVLB, establish the recommended dose schedule for future Phase 2 trials, determine drug kinetics and look for evidence of antitumor activity.
Roswell Park Cancer Institute is a division of the New York State Department of Health and a National Cancer Institute Designated Comprehensive Cancer Center. Roswell Park is the nation's first cancer research, treatment and education center and the third largest. Roswell Park brings together on one campus a staff of 2,700, including over 200 physicians, and senior scientists, oncology nurses, allied health professionals and lab technicians, all devoted to cancer care and research.
IGT is also pleased to announce the appointment of Gary N. Schwartz, M.D., to the Oncology Advisory Committee. Dr. Schwartz is a graduate from Stanford University School of Medicine. He is currently a clinical oncologist at the Department of Solid Tumor Oncology and Investigational Therapeutics, Division of Medicine, Roswell Park Cancer Institute. Dr. Schwartz is also the Assistant Professor of Medicine, State University of New York. His experience in clinical oncology and investigational drugs will bring further depth to IGT's cancer drug development programs.
IGT Pharma is a Vancouver based bio-pharmaceutical drug discovery company focused on the development of innovative solutions to target cancer and diseases of the central nervous system.
On behalf of the board of directors of IGT Pharma Inc. |
